Second-line Therapy for Type 2 Diabetes

被引：0
|
作者：
Krome, Susanne
机构：
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2024年 / 149卷 / 19期
关键词：
D O I：
10.1055/a-2329-7522
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
About 9% of the world's population is affected by type 2 diabetes. The disease is usually progressive and is associated with multiple complications. If metformin fails to effectively lower HbA1c, additive sulfonylureas, SGLT-2 inhibitors and DPP-4 inhibitors are the most commonly used drugs. Randomized studies have mainly compared their benefits with placebo. Target trial emulation enabled direct comparison.
引用
收藏
页码：1127 / 1128
页数：2
相关论文
共 50 条
  • [21] PATIENTS' PREFERENCES FOR NEWER SECOND-LINE PHARMACOLOGICAL AGENTS IN TYPE 2 DIABETES
    Banjara, B.
    Poudel, N.
    Garza, K. B.
    Westrick, S. C.
    Whitley, H. P.
    Ngorsuraches, S.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S566 - S566
  • [22] Patient Preferences Informing Choice of Second-Line Type 2 Diabetes Medications
    Golembiewski, Elizabeth
    Garcia, Andrea E.
    Polley, Eric
    Umpierrez, Guillermo
    Galindo, Rodolfo J.
    Brito, Juan
    Montori, Victor M.
    Mickelson, Mindy
    Mccoy, Rozalina G.
    [J]. DIABETES, 2023, 72
  • [23] Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes
    Liss, David T.
    Cherupally, Manisha
    O'Brien, Matthew J.
    Kang, Raymond H.
    Aikman, Cassandra
    Wallia, Amisha
    Cooper, Andrew J.
    Koep, Eleena
    Parker, Emily D.
    Ackermann, Ronald T.
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2023, 29 (12): : 661 - 668
  • [24] PATIENT PREFERENCES FOR SECOND-LINE MEDICATIONS TO MANAGE TYPE 2 DIABETES MELLITUS
    Ozdemir, Semra
    Baid, Drishti
    Verghese, Naina
    Lam, Amanda Yun Rui
    Lee, Phong Ching
    Ying, Lim Adoree Yi
    Zhu, Ling
    Finkelstein, Eric A.
    Goh, Su-Yen
    [J]. MEDICAL DECISION MAKING, 2020, 40 (01) : E286 - E287
  • [25] Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes
    Franchi, Matteo
    Pellegrini, Giacomo
    Avogaro, Angelo
    Buzzetti, Giuliano
    Candido, Riccardo
    Cavaliere, Arturo
    Consoli, Agostino
    Marzona, Irene
    Mennini, Francesco Saverio
    Palcic, Stefano
    Corrao, Giovanni
    [J]. BMJ OPEN DIABETES RESEARCH & CARE, 2024, 12 (03)
  • [26] Vascular events in patients with type 2 diabetes in the year following initiation of second-line therapy: the DISCOVER study
    Surmont, F.
    Chen, H.
    Cid-Ruzafa, J.
    Fenici, P.
    Gomes, M. B.
    Khunti, K.
    Pocock, S.
    Rathmann, W.
    Shestakova, M. V.
    Shimomura, I.
    Tang, F.
    Watada, H.
    Ji, L.
    Hammar, N.
    Kosiborod, M.
    [J]. DIABETOLOGIA, 2018, 61 : S562 - S562
  • [27] Choice of second-line antidiabetic treatment in Type 2 diabetes: influence of patient characteristics
    Zghebi, S. S.
    Steinke, D. T.
    Rutter, M. K.
    Ashcroft, D. M.
    [J]. DIABETIC MEDICINE, 2015, 32 : 205 - 205
  • [28] Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China
    Gu, Shuyan
    Deng, Jing
    Shi, Lizheng
    Mu, Yiming
    Dong, Hengjin
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (10) : 808 - 820
  • [29] Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States
    Reifsnider, Odette
    Pimple, Pratik
    Stargardter, Matthew J. D.
    Brand, Sarah
    Desai, Nihar
    Shetty, Sharash
    [J]. DIABETES, 2020, 69
  • [30] Vascular Events in Patients with Type 2 Diabetes in the Year following Initiation of Second-Line Therapy-The DISCOVER Study
    Kosiborod, Mikhail
    Chen, Hungta
    Cid-Ruzafa, Javier
    Fenici, Peter
    Gomes, Marilia B.
    Khunti, Kamlesh
    Pocock, Stuart
    Rathmann, Wolfgang
    Shestakova, Marina V.
    Shimomura, Iichiro
    Surmont, Filip
    Tang, Fengming
    Watada, Hirotaka
    Ji, Linong
    Hammar, Niklas
    [J]. DIABETES, 2018, 67
12345